New hope for toddlers with rare epilepsy: ganaxolone trial begins
Disease control
Not yet recruiting
This study tests whether adding ganaxolone to standard seizure medication can reduce seizures in children aged 6 months to 2 years with CDKL5 deficiency disorder, a rare genetic condition. About 20 children will receive either ganaxolone or a placebo for 12 weeks to see if it saf…
Phase: PHASE3 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated May 17, 2026 17:10 UTC